Rhesus macaques with SARS-CoV-2 develop promising immune response
A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.
List view / Grid view
A study has shown that the immune response of rhesus macaques with SARS-CoV-2 could be reproduced with a vaccine.
A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
The natural language processing model trained using viral protein sequence data was able to predict promising targets for vaccines against HIV, influenza and coronaviruses.
Researchers have shown in cells and models that the central nervous system and neurons can become a target of SARS-CoV-2 infection.
Researchers have shown rhesus macaques and baboons develop strong signs of acute viral infection from SARS-CoV-2, making them ideal models.
A new study suggests that inflammation and blood vessel damage may be the primary causes of neurological symptoms in COVID-19 patients, instead of the virus infecting the brain.
Baidyanath Dash explains the two requirements for COVID-19 drug development: killing the virus and boosting immunity.
Dr Isaac Karimi and his team explain how compounds to treat COVID-19 could be found in Kurdish ethnomedicine, selecting some plants for computational drug discovery.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.
The study found five key genetic differences when they compared sequences from severe COVID-19 patients to healthy individuals.
Scientists shows targeting cholesterol or phosphatidylinositol phosphate (PIP) could be a promising strategy to combat multiple coronaviruses.
Study suggests reducing the expression of the methyl-CpG-binding domain 2 (MBD2) protein on macrophages could be a viable therapeutic strategy for lung fibrosis.
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
The new study shows how SARS-CoV-2 significantly remodels cellular processes in just an hour and identifies potential drug targets and therapeutics for COVID-19.
Researchers have shown that the presence of the inflammasome mediated by NLRP3 is a marker and drug target for COVID-19-related cytokine storms.